Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)

Group 1 - MoonLake Immunotherapeutics (NASDAQ:MLTX) is considered one of the best stocks to buy for the next three months according to hedge funds, with a Buy rating and a price target of $73 set by Leerink Partners analyst Thomas Smith [1][2] - The company's drug Sonelokimab is highlighted for its potential in treating moderate-to-severe hidradenitis suppurativa, with the upcoming Phase 3 VELA trial results expected to be a key catalyst for the stock [2][3] - Recent completion of patient enrollment in the VELA trial, along with favorable baseline characteristics resembling the successful Phase 2 MIRA study, supports the analyst's optimism [3] Group 2 - Key dermatology experts have expressed favor for Sonelokimab, citing its better efficacy, safety, and dosing convenience compared to competitors, which is expected to drive strong sales growth for the drug by 2035 [3] - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory skin and joint diseases [4]